fon-2021-1437_suppl_data

<b>Table 1. </b> Erosion Score
Locations<b></b>
<b>Table 2. </b>Cartilage Score Locations<b></b>
<b>Table 3. </b>Bone<b> </b>Marrow Edema/Infiltration<b> (</b>BME) Score
Locations<b></b>
<b>Table 4. </b>Knee Locations and Scores<b></b>
<b>CSF1 Receptor Inhibition of Tenosynovial Giant Cell Tumor Using Novel
Disease-Specific MRI Measures of Tumor Burden</b>

Abstract

<b>Background:</b> Monitoring treatment of tenosynovial giant cell
tumor (TGCT) is complicated by irregular shape and asymmetrical growth of the
tumor. We compared responses to pexidartinib
by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 with those
to Tumor Volume Score (TVS) and modified-RECIST (m-RECIST). <b>Methods: </b>MRIs acquired every 2 cycles
were assessed centrally using RECIST 1.1, m-RECIST, and TVS and tissue damage
score (TDS). <b>Results: </b>Thirty-one evaluable TGCT patients were
treated with pexidartinib. From baseline to last visit, 94% of patients
(29/31) showed a decrease in tumor size (median change: −60% [RECIST], −66%
[m-RECIST], −79% [TVS]). All methods showed 100% disease control rate. For TDS,
improvements were seen in patients bone loss (36%), bone marrow edema (58%),
knee effusion (46%). <b>Conclusions: </b>TVS
and m-RECIST offer potentially superior alternatives to conventional RECIST for
monitoring disease progression and treatment response in TGCT. TDS adds
important information about joint damage associated with TGCT.<b><br></b>